Ye’ELa Scharff
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ye’ELa Scharff has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Lea Monteran
Tel Aviv University 1 Department of Pathology, Gray Faculty of Medical and Health Sciences Tel Aviv, Israel
23 shared publications - Neta Erez
Department of Pathology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
23 shared publications - Nour Ershaid
Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
20 shared publications - Yael Zait
Tel Aviv University 1 Department of Pathology, Gray Faculty of Medical and Health Sciences Tel Aviv, Israel
20 shared publications - Noam Cohen
Department of Pathology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
17 shared publications - Asaf Aizic
Tel Aviv Sourasky Medical Center 4 Institute of Pathology Gray Faculty of Medical and Health Sciences Tel Aviv, Israel
14 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Data from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
High-grade serous (tubo-ovarian) carcinoma (HGSC) is the most lethal gynecologic malignancy and the most common form of ovarian cancer. Most patients (75%) are diagnosed at advanced disease stages, with widespread peritoneal dissemination leading to a poor prognosis. In this study, we characterized the interactions between fibroblasts and immune cells that facilitate the formation of a hospitable niche in metastatic peritoneal ovarian cancer. Analysis of the dynamic changes in cancer-associated fibroblasts (CAF) and immune cells isolated from patients with HGSC and mouse models revealed transcriptional reprogramming during HGSC progression. Functionally, peritoneal fibroblasts promoted myeloid cell recruitment and T-cell dysfunction. Distinct peritoneal metastatic niches featured reciprocal communication between fibroblasts and T cells. In human HGSC peritoneal metastases, the TIGIT–CD155 immune checkpoint signaling axis was upregulated in T cells and CAFs, respectively, and correlated with worse outcomes. This study implicates CAFs as key modulators of the immune microenvironment in intraperitoneal HGSC metastasis and provides potential avenues for therapeutic intervention of stromal–immune interactions to inhibit the metastatic spread of ovarian carcinoma. Significance:Fibroblast-T cell interactions shape a permissive metastatic niche to support intraperitoneal metastasis of ovarian cancer and offer a promising immunotherapeutic target to interrupt disease progression.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
High-grade serous (tubo-ovarian) carcinoma (HGSC) is the most lethal gynecologic malignancy and the most common form of ovarian cancer. Most patients (75%) are diagnosed at advanced disease stages, with widespread peritoneal dissemination leading to a poor prognosis. In this study, we characterized the interactions between fibroblasts and immune cells that facilitate the formation of a hospitable niche in metastatic peritoneal ovarian cancer. Analysis of the dynamic changes in cancer-associated fibroblasts (CAF) and immune cells isolated from patients with HGSC and mouse models revealed transcriptional reprogramming during HGSC progression. Functionally, peritoneal fibroblasts promoted myeloid cell recruitment and T-cell dysfunction. Distinct peritoneal metastatic niches featured reciprocal communication between fibroblasts and T cells. In human HGSC peritoneal metastases, the TIGIT–CD155 immune checkpoint signaling axis was upregulated in T cells and CAFs, respectively, and correlated with worse outcomes. This study implicates CAFs as key modulators of the immune microenvironment in intraperitoneal HGSC metastasis and provides potential avenues for therapeutic intervention of stromal–immune interactions to inhibit the metastatic spread of ovarian carcinoma. Significance:Fibroblast-T cell interactions shape a permissive metastatic niche to support intraperitoneal metastasis of ovarian cancer and offer a promising immunotherapeutic target to interrupt disease progression.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 1 shows analysis of ovarian cancer scRNA-seq datasets.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 1 shows analysis of ovarian cancer scRNA-seq datasets.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 2 shows isolation of omental and peritoneal CAFs.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 2 shows isolation of omental and peritoneal CAFs.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 3 shows gating strategy for analysis of the immune milieu in distinct metastatic niches.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 3 shows gating strategy for analysis of the immune milieu in distinct metastatic niches.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 4 shows analysis of the immune milieu in peritoneum and ascites.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 4 shows analysis of the immune milieu in peritoneum and ascites.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 5 shows that fibroblasts drive T cell dysfunction via direct contact.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 5 shows that fibroblasts drive T cell dysfunction via direct contact.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 6 shows gating strategy for Analysis of immune checkpoint receptors and ligands.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 6 shows gating strategy for Analysis of immune checkpoint receptors and ligands.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Table S1 shows patient and tissue sample information.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Table S1 shows patient and tissue sample information.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 7 shows that the TME in metastatic HGSC human tumors is vastly diverse.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Figure 7 shows that the TME in metastatic HGSC human tumors is vastly diverse.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Table S3 lists immunofluorescence antibodies used.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Stromal–Immune Interactions Promote Immune Suppression in Intraperitoneal Metastasis of Ovarian Carcinoma
Supplementary Table S3 lists immunofluorescence antibodies used.